INTRODUCTION
The world's largest group of Familial Amyloid Polyneuropathy (FAP) occurs in Portugal.
1 This is a chronic autosomal dominant, multisystem and gradually disabling disease (in other words, there is a 50% probability of Valdrez K, et (CHP) . From these, 54% are female, 80% are aged under 55 and 27% are asymptomatic. The disease is mostly prevalent in Póvoa de Varzim/Vila do Conde, Braga and Barcelos' municipalities.
Transmission may be avoided when carriers decide not having biological children, when confirmation is undertaken in Prenatal Diagnosis (PND) resulting in a Voluntary Termination of Pregnancy (VTP) when the foetus is affected or when Pre-implantation Genetic Diagnosis (PGD) -allowing for embryo FAP screening and selection before their transfer to the uterus. Based on the importance assigned to genetic paternity in the construction of human individual and collective identity, mainly in the Portuguese society, 3 as well as to emotional and healthcare costs involved in VTP, 4 PGD is available to be used whenever any FAP carrier wishes to have a child. 5 PGD is available in Portugal since 1997 6 and the first protocol involving its use in FAP was published in 2001.
7
FAP was considered in December 2012 one of the major diseases eligible for PGD by the National Council for Medically-Assisted Procreation (Conselho Nacional de Procriação Medicamente Assistida [CNPMA]) 8 , meeting all the requirements for such classification: FAP induces a significant suffering and/or premature death; its genetic causality has been established and there is a clear relationship between the presence of a genetic change and the presence (or high risk) of disease in carriers; there is a technical possibility of identification of an embryo or oocyte genetic defect, there is over 90% reliability of the genetic screening test and the risk of transmission to the offspring is significantly higher than the risk in general population. 9 This may allow Medically-Assisted Procreation (MAP) techniques to be made available to these patients, one of the objectives established by the World Health Organization (WHO) for this millennium. [10] [11] [12] This issue was considered by the Portuguese Government since the publication of the first legislation regarding the use of these techniques in 2006, together with the standardization of healthcare costs and quality assessment over the subsequent years. 13, 14 The PGD must follow a genetic counselling program carried out by a clinical geneticist and compulsory consent from both partners should be obtained. 9 In addition, PGD application must be oriented by a clinical geneticist together with a multidisciplinary team including reproduction medicine specialists, embryologists, clinical geneticists, cytogeneticists and molecular geneticists. 15 PDG recommendations were published in Feb 2013 by the CNPMA providing data on the number of treatments and their indication, as well as the results of the confirmatory PND, when obtained, to be included on the annual report of the MAP centres. 9 However, there is still no national data register regarding the use of PDG by FAP carriers. Therefore, our study aimed to determine the prevalence of the use of PDG in FAP carriers at the UCP from the CHP and to identify any associated factors.
MATERIAL AND METHODS
Our study was carried out at the UCP from the CHP. Our study's protocol was approved by the Administration Board of the Centro Hospitalar do Porto, upon approval by the Ethics Committee for Health and by the Research Coordination Department, as well as by the Clinical Directory. All participants gave their written informed consent at the time of completing the questionnaire.
The number of FAP Portuguese carriers was established in March 2011 by our Department, based on the information collected from the following healthcare units and professionals: clinical units where FAP carriers were followed in Porto and Lisbon; liver transplantation units in Lisbon, Coimbra and Porto, responsible physicians for outpatient FAP departments in the municipalities of Covilhã, Seia, Figueira da Foz, Barcelos and Esposende; Associação de Paramiloidose (FAP Association) and their local groups of patients. According to these data, there is an estimated number of 1,657 FAP carriers in Portugal, 64% (n = 1,055) of which are followed by our unit (non-published report).
All our patients aged between 18 and 55 were considered as eligible for inclusion in our study and, in December 2012, 913 patients met these criteria. Between January and May 2013, 271 FAP carriers were consecutively invited to be included in the study, ensuring a 5% significance level and a 95% statistical significance. A representative sample of 266 carriers was systematically selected, corresponding to a 98.2% participation percentage.
The patients were selected at the time of a routine programmed medical control by several specialties (Neurology, Nephrology, Psychiatry and Ophthalmology, among others). Two health professionals were selected to invite the eligible carriers for inclusion in the study, following the unit's normal operation and availability, in order to obtain a participant's daily, consecutive and systematic selection. A program leaflet was handed to every eligible carrier, asking for cooperation and explaining possible doubts.
Patient's demographic and socio-economic data were obtained, based on a self-administered questionnaire, This analysis is based on 111 patients with a life cycle that included the possibility of facing a decision of using or not using the PGD. These were patients with prior family diagnosis describing having been involved at least once in a pregnancy attempt after the 31st December 2001, the year when the first protocol of application of PGD to the FAP was published.
7 Full information regarding all variables included in the final model was available for 107 of these patients.
The statistical analysis was carried out using the STATA 11.0 (College Station, TX, 2009) software. The prevalence of PGD use is shown with a 95% confidence interval (95% CI). Chi-square test was used for comparison of proportions. Gross and adjusted odds ratio (OR) were estimated with 95% CI by logistic regression, in order to assess PGD userelated factors. Multivariate models were built using the variables showing a statistically significant association with the use of PGD in this sample or those that researchers considered to be potential biases to this association. Those variables that did not show an independent association with the use of PGD and that did not bias the effect of the remaining variables were excluded from the final model.
RESULTS
In our study, 61.3% of the patients were female and half of them were aged 35 or above (Table 1) . Approximately 70% lived in the municipalities of Braga or Porto and more than 90% had already lived in cohabitation. In our group of patients, 46% had over 12-years schooling, 76.4% were employed and approximately 42% had a household monthly income above 1,000€, while only 13.8% were considered from higher/middle higher social class. More than 95% of FAP carriers referred as following a religion and Catholic religion was more frequently referred (88.3%). Approximately 60 and 85% of the patients were diagnosed with FAP and had children after 2001, respectively. PND was referred by 20% of the patients.
From the 111 PGD-eligible carriers or, in other words, from those with a FAP diagnosis that referred a pregnancy attempt upon the 31st December 2001, a 20.7% prevalence of PGD use was found (95% CI 13.6-29.5). The patients that underwent PGD had mostly over 12-years schooling (73.9% vs. 38.6%; p = 0.003), over 1,000 € family monthly income (72.7% vs. 33.7%; p = 0.001) and were considered more frequently in higher/middle higher social class (27.3% vs.10.3%; p = 0.039) when compared to those that never underwent PGD. FAP carriers diagnosed (39.1% vs. 65.9%, p = 0.019) and with children born after 2001 (65.2% vs. 90.9%, p = 0.002) showed statistically significant less tendency to become PGD-users. We did not find any statistically significant differences between PGD-users and non-users regarding gender, patient's age, place of residence, marital status, professional status, religion and PND use ( Table 1) .
The main factors associated to the use of PGD by FAP carriers are shown in Table 2 . Upon adjustment to patient's age, gender and all the variables significantly associated to the PGD use, only the associations regarding family income, the date of diagnosis and child's birth after 2001 remained statistically significant. Therefore, the described statistic effects regarding the schooling level and subjective social class seem to be explained by the effect of income, which stands out as the most relevant socio-economic factor to the use of PGD. FAP carriers diagnosed after 2001 (OR = 0.15; 95% CI 0.04-0.57) and with children born after that year (OR = 0.07; 95% CI 0.02-0.32) showed a significantly lower prevalence of PGD use when compared to those diagnosed and with children born before 2001, respectively. Household income was directly associated to PGD use by FAP carriers (OR = 11.87; 95% CI 2.87-49.15).
DISCUSSION
Our study assessed for the first time ever, to the best of our knowledge, the prevalence of PGD use by Portuguese FAP carriers. Considering that Portugal is the most affected country with the disease involving severe, disabling clinical manifestations with a major impact on patient's quality of life and survival, the prevalence of PGD use is an important indicator. Our results showed that 20% of FAP carriers used PGD and that a higher family income is directly associated to the use of this technique, while an individual diagnosis and a birth after 2001 showed to be inversely associated to the use of PGD. The only publicly disclosed data regarding this issue was an oral presentation at the European Advanced Postgraduate Course on Transthyretin Amyloidosis, held in May 2013 at the CHP (Filipa Carvalho, unpublished data). We found that, between January 1999 and May 2013, 62 male and 36 female FAP carriers underwent PGD at the Centro Hospitalar de S. João, the only public healthcare centre where this test is available. In total, 186 PGD cycles were performed (136 cycles followed and 50 non-followed by embryo transfer), 40 clinical pregnancies were confirmed (28 single, seven multiple, three ongoing and two terminations), from which 43 children were born. Therefore, 98 carriers underwent PGD in our unit, at a time when a total of 1,657 FAP carriers were estimated to exist in Portugal (March 2011), 64% (n = 1,055) of which were followed at the UCP from the CHP. Our results regarding the prevalence of PGD use in our unit are in line with these data, considering that our patients underwent PGD both at our public healthcare centre and in other private MAP centres. Our results should be considered within the social, cultural, political and economic context on which the availability of these techniques (and particularly PGD) is based on. Free access (subject to return) to support clinical equipment and full reimbursement of medication is available to patients with 70% or higher disability. 16, 17 However, the current public funding of PGD only includes couples with a female partner aged below 40 and with no more than one child in common at the time of undergoing this technique 18 and these therapies are not covered by private health insurances. A price of 2,613 € for each intracytoplasmic sperm injection (ICSI) therapy was established by the Ordinance (Portaria n.º 67/2011), 19 lower than the price charged in a private centre of 4,200 € for a complete ICSI cycle, in addition to 450 € for the PGD through embryo biopsy. 20 These factors may certainly explain the use of PGD by FAP carriers with a higher family income.
This conclusion is supported by the results found by a recent systematic review regarding the factors influencing the couple's decision process as regards the use of PGD 21 which emphasizes the importance of cognitive evaluation of the financial costs involved in PGD. This evaluation should include other factors that were not included in our study, namely the estimated time delay to pregnancy, as well as the complex and uncertain information regarding the relatively low success rates and the awareness of the short and long-term risk involved in medical procedures. 22, 23 In addition, the emotional responses associated to pain and suffering and the meaning of happiness have an important role in this decision process, 24 as well as the attitudes and social roles regarding the status of the human embryo and the moral acceptability of the use of techniques oriented towards disease-prevention. 25, 26 The decision of PGD users is also influenced by factors as the time needed to organize, to program and to attend to medical appointments, as well as the number and type of education and counselling sessions with health professionals (like for instance with genetic specialists and psychologists).
27 Therefore, the identification of major factors influencing the decision regarding the use of PGD shows the complexity, dynamics and interactivity of information processing in this area, as well as the heterogeneity of the meanings assigned by users to genetic risk associated to their reproductive life. 28 These elements are crucial to explain the reason why FAP diagnosis and children born before 2001 are associated to the use of PGD by FAP carriers. These patients may have identified their risk condition or may have been involved in longer-established paternity active approaches with more chances to know the technique and to consider the different reproductive options as they become more aware about the outcomes of the disease.
We should note that all the patients diagnosed after 2001 had a family diagnosis of the disease when they were involved in a pregnancy attempt, which may show a more or less clearly expressed attempt not to know the results of the individual diagnosis before having a child or the perception of FAP as a family heritage. In addition, the failure to use PGD may be associated to concerns regarding the status of the human embryo and to the possible relationship of this technique to stigmatization, intolerance and discrimination of FAP carriers. 25, 26, 29 However, these reasons were very rarely selected by the patients to explain not using the PGD and financial costs, lack of confidence on the technique and time delay to pregnancy were the major reasons for such an option. 30 Therefore, it is important to promote the access to PGD, as well as to support awareness and information campaigns aimed to release correct knowledge regarding this technique, particularly among FAP carriers.
CONCLUSION
The low prevalence of PGD use by FAP carriers shows the need to understand how the information is processed by the carriers and how the risk is assessed by the PGD, in order to promote interventions aimed to increase compliance to the technique. In addition, the less frequent use of PGD by carriers with a lower family income shows the importance of improving the access to PGD in FAP in order to prevent spreading of the disease and to reduce disparities regarding healthcare access and use.
